Share this article and save a life!
Pancreatic cancer has always been a silent killer, often detected too late for effective treatment. But a breakthrough AI system might change everything about how we fight this disease.
Microsoft and collaborating researchers have developed a deep learning model that can detect pancreatic ductal adenocarcinoma up to THREE YEARS before clinical diagnosis using standard non-contrast abdominal CT scans.
🔍 Why this matters:
• Pancreatic cancer is one of the deadliest cancers with a 5-year survival rate of just 12%
• Early detection is extremely challenging with current methods
• Most patients are diagnosed at advanced stages when treatment options are limited
🧠 The technical breakthrough:
The AI model achieved an AUROC (a measure of accuracy) above 0.92 in preprint studies, demonstrating robust performance across multiple patient cohorts. What makes this truly revolutionary is that it works with ROUTINE CT scans that millions of patients already get for other reasons, requiring no special protocols or additional testing.
🏥 Real-world implications for healthcare providers:
• Opportunity to identify high-risk patients years earlier
• Potential to significantly improve survival rates through earlier intervention
• Could be integrated into existing radiology workflows with minimal disruption
Clinical trials are scheduled to begin in the U.S. and Europe before the end of 2025, with Microsoft planning to release a research API this fall.
For imaging centers and hospitals, this represents a prime example of how AI can transform detection capabilities without requiring new equipment investments, potentially saving more lives while working within existing infrastructure.
Could tools like this finally change pancreatic cancer from a death sentence to a manageable condition? I believe we’re getting closer.
What AI detection breakthroughs are you most interested in seeing in radiology and diagnostics?
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
